Pilot Study of Hemospan® in Patients With Chronic Critical Limb Ischemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00633659|
Recruitment Status : Completed
First Posted : March 12, 2008
Last Update Posted : August 19, 2013
|Condition or disease||Intervention/treatment||Phase|
|Vascular Disease Critical Lower Limb Ischemia||Drug: Hemospan (MP4OX) Drug: Voluven (HES 130/0.4)||Phase 2|
Hemospan® is a novel hemoglobin-based oxygen carrier developed to perfuse and oxygenate tissue at risk for ischemia and hypoxia. Because of its molecular size and oxygen binding characteristics, Hemospan selectively off-loads oxygen in tissues predisposed to low oxygen tension. Preclinical evidence suggests that Hemospan provides volume expansion and enhances tissue perfusion. Hemospan is therefore being developed as an oxygen-carrying plasma expander for patients where tissues are at risk of inadequate perfusion and oxygenation.
In patients with chronic critical lower limb ischemia (CCLI), the primary cause of ischemic symptoms in the leg is insufficient perfusion. As many of the patients suffering from CCLI are elderly and have concomitant disease, surgical procedures may not always be possible. The goal of all treatments is to improve the blood flow in the nutritional vessels of the ischemic areas; one such possibility may be to use an oxygen-carrying plasma expander.
Hemospan has been shown to improve the oxygenation of tissues by preserving functional capillary density. In addition, Hemospan has a high affinity for oxygen - a feature that is specifically designed to target the unloading of oxygen in the microcirculation where local PO2 levels are much lower (e.g., in ischemic regions). Since Hemospan is a cell-free oxygen carrier, it should be able to perfuse capillaries that are so constricted that red blood cells are unable to flow through them.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||6 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||A Phase II Study of Hemospan® Versus Voluven® to Evaluate Vascular Resistance and Forearm Blood Flow, and to Assess Local Skin Blood Flow and Tissue Oxygenation in the Ischemic Foot of Patients With Chronic Critical Limb Ischemia|
|Study Start Date :||September 2007|
|Actual Primary Completion Date :||June 2008|
|Actual Study Completion Date :||December 2008|
Experimental: Hemospan (MP4OX)
4.3 g/dL MalPEG-Hb solution
Drug: Hemospan (MP4OX)
250 mL of Hemospan (MP4OX)
Voluven (HES 130/0.4)
Drug: Voluven (HES 130/0.4)
250 mL of Voluven (HES 130/0.4) solution
- To investigate the effect of Hemospan on vascular resistance by evaluating blood flow in the forearm [ Time Frame: 4 hours ]
- To evaluate the effects of Hemospan on local skin blood flow and tissue oxygenation in an ischemic region of the foot [ Time Frame: 4 hours ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00633659
|Principal Investigator:||Pär Olofsson, MD, PhD||Karolinska University Hospital|